The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global large volume parenteral (LVP) market reached a value of US$ 8.58 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 12.9 Billion by 2027, exhibiting a CAGR of 6.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A large volume parenteral (LVP) is a single-dose injection packaged in a glass bottle or a flexible container of more than 100ml capacity after sterilization via heat. It is injected through the skin or other external boundary tissue to directly administrate the active drug substances into the blood vessels, organs, tissues, or lesions. It generally consists of an active ingredient, water-miscible or non-aqueous vehicle, and added substances like buffers, antioxidants, preservatives, surfactants, antimicrobial agents, and tonicity adjusters. Some of the commonly available LVPs around the world are peritoneal dialysis, irrigating solutions, blood derivatives, drug premixes, and contrast agents.
The rising prevalence of malnutrition, growing natality rate, and increasing premature births worldwide are among the key factors catalyzing the demand for LVPs to administer a large amount of nutrients in patients who are unable to take food orally. Apart from this, they are widely used in administering essential nutrients to patients undergoing treatment for esophageal obstruction, gastrointestinal (GI) diseases, cancer, and ulcer. In addition, LVPs find extensive application in heart surgery to prevent ischemic injury to the myocardium during reperfusion and the blood flow supply restriction. This, in confluence with the escalating demand for safe, fast, and effective methods of drug administration among patients undergoing surgical interventions, is contributing to the market growth. Besides this, the growing consumption of fast food across the globe has resulted in rising instances of non-communicable diseases, such as hypertension, diabetes, obesity, and other metabolic disorders. This, in turn, is positively influencing the adoption of LVPs that are a mixture of dextrose, amino acids, lipids, added electrolytes, trace metals, and vitamins.
IMARC Group provides an analysis of the key trends in each sub-segment of the global large volume parenteral (LVP) market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, volume, application and end users.
Breakup by Type:
Breakup by Volume:
Breakup by Application:
Breakup by End Users:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Albert David Ltd., B. Braun Melsungen AG, Baxter International Inc., BML Parenteral Drugs, Fresenius Kabi AG, Grifols S.A, Otsuka Pharmaceutical Co. Ltd, Pharmaceutical Solutions Industry Ltd., Sichuan Kelun Pharmaceutical Co. Ltd. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Volume, Application, End Users, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Albert David Ltd., B. Braun Melsungen AG, Baxter International Inc., BML Parenteral Drugs, Fresenius Kabi AG, Grifols S.A, Otsuka Pharmaceutical Co. Ltd, Pharmaceutical Solutions Industry Ltd., Sichuan Kelun Pharmaceutical Co. Ltd. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at